AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
AgeX Therapeutics, Inc. (AGE)
Company Research
Source: GlobeNewswire
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights. Recent Highlights ?Stockholders approved transactions for merger with Serina Therapeutics, Inc. ?Obtained $4.4 million addition to line of credit from Juvenescence Limited ?Preferred Stock converted into Common Stock ?Completed reverse stock split at a ratio of 1 for 35.17 Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness and Conversion to Common Stock During July 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant to which AgeX issued shares of Series A Preferred Stock and Series B Preferred Stock to Juvenescence in exchange for the extinguishment of a total of $36 million of in
Show less
Read more
Impact Snapshot
Event Time:
AGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGE alerts
High impacting AgeX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AGE
News
- Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics [Yahoo! Finance]Yahoo! Finance
- AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXXPR Newswire
- AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGEBusiness Wire
AGE
Sec Filings
- 3/26/24 - Form SC
- 3/22/24 - Form 10-K
- 3/22/24 - Form 8-K
- AGE's page on the SEC website